Last reviewed · How we verify
Non-small cell lung cancer, negative for epidermal growth factor receptor expression
Approved treatments
- IMJUDO · ASTRAZENECA AB
- Imjudo · AstraZeneca
Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-small cell lung cancer, negative for epidermal growth factor receptor expression patent landscape — cliff calendar, originator estates, attackable patents
- Non-small cell lung cancer, negative for epidermal growth factor receptor expression treatment landscape brief
- Non-small cell lung cancer, negative for epidermal growth factor receptor expression treatment updates RSS
Frequently asked questions about Non-small cell lung cancer, negative for epidermal growth factor receptor expression
What drugs treat Non-small cell lung cancer, negative for epidermal growth factor receptor expression?
Tracked treatments include IMJUDO, Imjudo.
What is the treatment for Non-small cell lung cancer, negative for epidermal growth factor receptor expression?
Standard treatment for Non-small cell lung cancer, negative for epidermal growth factor receptor expression includes IMJUDO, Imjudo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-small cell lung cancer, negative for epidermal growth factor receptor expression patent cliff · Non-small cell lung cancer, negative for epidermal growth factor receptor expression CI report
- Treatment: IMJUDO · ASTRAZENECA AB
- Treatment: Imjudo · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing